From: Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
Items | Cox’s regression model | |||
---|---|---|---|---|
p value | HR | 95%CI | ||
Lower | Higher | |||
Univariate Cox’s regression | ||||
Circ-SMARCA5 (high vs low) | 0.006 | 0.474 | 0.278 | 0.806 |
Age (≥60 years vs < 60 years) | 0.390 | 1.255 | 0.748 | 2.106 |
Gender (male vs female) | 0.122 | 0.663 | 0.393 | 1.116 |
Immunoglobulin subtype | ||||
IgG vs others | 0.583 | 0.865 | 0.516 | 1.450 |
IgA vs others | 0.423 | 1.272 | 0.706 | 2.290 |
IgM vs others | 0.720 | 1.436 | 0.198 | 10.423 |
IgD vs others | 0.873 | 0.851 | 0.117 | 6.178 |
Bence-Jones protein vs others | 0.847 | 0.935 | 0.472 | 1.850 |
Hb (≥10 g/dL vs < 10 g/dL) | 0.908 | 0.970 | 0.578 | 1.626 |
Calcium ≥11.5 mg/dL vs < 11.5 mg/dL) | 0.749 | 0.906 | 0.497 | 1.655 |
Scr (≥2 mg/dL vs < 2 mg/dL) | 0.005 | 2.261 | 1.282 | 3.990 |
ALB (≥3.5 mg/dL vs < 3.5 mg/dL) | 0.792 | 1.080 | 0.612 | 1.905 |
β2-MG (≥5.5 mg/L vs < 5.5 mg/L) | < 0.001 | 22.970 | 9.519 | 55.426 |
LDH (≥220 U/L vs < 220 U/L) | 0.480 | 1.219 | 0.703 | 2.113 |
Durie-Salmon stage (III vs I&II) | 0.320 | 1.302 | 0.774 | 2.191 |
ISS stage (III vs I&II) | < 0.001 | 22.970 | 9.519 | 55.426 |
Bone lesion (yes vs no) | 0.239 | 0.705 | 0.393 | 1.262 |
Cytogenetics abnormality | ||||
t (4; 14) translocation (yes vs no) | 0.947 | 0.972 | 0.413 | 2.286 |
t (14; 16) translocation (yes vs no) | 0.589 | 0.804 | 0.365 | 1.773 |
Del (17p) (yes vs no) | 0.453 | 1.313 | 0.644 | 2.676 |
Multivariate Cox’s regression with Forward Stepwise (Conditional) method | ||||
Durie-Salmon stage (III vs I&II) | 0.002 | 2.350 | 1.363 | 4.053 |
ISS stage (III vs I&II) | < 0.001 | 32.620 | 12.739 | 83.528 |